|Institute for Research & Innovation|
- Institute for Research & Innovation
- About Us
- Participate in a Study
- Become an Investigator
- Information for Sponsors
Multiple Sclerosis - Relapse (Ages 18-85)TItle: A Phase 1B, Randomized, Placebo Controlled, Multiple Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Multiple Sclerosis
Purpose: Primary objective is to evaluate the safety and tolerability of Human Placenta-Derived Cells administered IV to patients with relapsing remitting MS or secondary Progressive MS. Infusion of placental derived stem cells (from full-term live births, donated by parents) occurs on two occasions, 1 week apart and then the patient is follow closely for 2 years. Patients do no need to stop current disease modifying treatment.
Who Can Participate?
Diagnosis or Condition: Patients with relapsing remitting or secondary progressive Multiple Sclerosis with relapse in last year
Age: 18 to 85 years old
Sex: Males and Females
Visits: 7 visits over a period of 13 weeks.
Stipend: You will be compensated for your time and travel
Principal Investigator: John R. Huddleston, MD, FAAN
Study Coordinator: Sandra Reilley, MD, CPI, 253.403.7440
For more information, contact the Study Coordinator and reference Celgene Trial.